Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years.

Ozempic has helped many make significant strides in their weight loss journey. The diabetes drug that also aids in weight loss works by activating GLP-1 receptors, which reduce hunger and control cravings.

Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, and their potential downsides is key to making informed decisions.

The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed pounds.

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued weight loss. While well-tolerated, further long-term studies are needed to evaluate its safety and efficacy.

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist.

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself “at my ideal body weight,” with his cholesterol below 200 for the first time in 20 years.